apceth Received Extended Manufacturer's Licence for Somatic Cell Therapeutics At The Ottobrunn Site
Advertisement
Adult stem cell research at the highest level will be possible at the new apceth site in Ottobrunn near Munich, Germany: in August 2011, the Munich biotech company was granted a manufacturer's licence pursuant to Section 13, German Medicines Act, for the production of somatic cell therapeutics at the new research and production facilities. Together with the already operational site at Munich Großhadern, apceth now has two highly efficient and GMP-compliant building complexes that have cleared the high certification hurdle. "Thanks to the new capacity, we are now in the position to push ahead more quickly with our own development projects and to offer our know-how and our premises to co-operation partners", explained apceth CEO Dr Christine Günther. CSO Prof. Ralf Huss added: "This has enabled us to further close the gap between research and clinical application".
1,800 square metres for research
The apceth site in Ottobrunn covers a total of 1,800 square metres, of which 457 m2 are cleanroom space. Thus, together with the GMP premises in Großhadern, apceth now has a total of 600 m2 cleanroom space at its disposal. This is divided among five separate cleanroom suites (ISO8, ISO7, ISO5). The units are equipped with storage tanks for liquid nitrogen for storing the cell preparations and a total of six incubators for cell expansion. These are monitored around the clock by the company's own Quality Control staff.
Other news from the department manufacturing
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Successful Exit: PerkinElmer Agrees to Acquire SIRION Biotech - SIRION Biotech will continue to grow its position in viral vector technologies for cell and gene therapy as part of PerkinElmer
Novartis merges with Alcon - Novartis Board of Directors unanimously approves merger for a value of USD 168 per Alcon share totaling USD 12.9 billion, comprising share consideration of up to 2.8 Novartis shares and a contingent cash payment
Researchers predict cell conversion factors - Potential for regenerative medicine
Category:Neuroprosthetics
Low-level arsenic exposure before birth associated with early puberty and obesity
Marshall-Smith_syndrome
An intestinal chip model takes research of fungal infections to a new level - Successful cooperation between science, clinic and start-up
Hodulcine